JPRN-UMIN000021757Recruiting未知
A prospective study of efficacy and safety of lenvatinib in patients with RAI-refractory differentiated thyroid cancer patients - Liberty-study (Efficacy and benefit of lenvatinib after resistance to I-131 treatment for differentiated thyroid cancer)
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Enrollment
- 320
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •a) undifferentiated and medullary carcinoma b) prior therapy with lenvatinib c) preteninuria d) with severe heart failure e) bleeding/atherothrombotic disorder, or use of anticoagulants f) with another active malignant tumors g) pregnant and/or lactating women h) judged to be unfit to this study by investigater
Investigators
Similar Trials
Completed
Phase 4
The study to evaluate the efficacy and safety of linear high intensity focus ultrasound for enlarged pores in Thailand, Pilot studyHealthy human volunteersHigh intensity focused ultrasoundFaceSkinTCTR20220701006Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand30
Completed
Phase 4
The study to evaluate the efficacy and safety of linear high intensity focus ultrasound for lower face sagging in Thailand, A pilot studyHealthy human volunteersHigh intensity focused ultrasoundFaceSkinTCTR20220629011Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand30
Completed
Phase 4
The study to evaluate the efficacy and safety of linear high intensity focus ultrasound for upper face laxity in Thailand, Pilot studyHealthy human volunteersHigh intensity focused ultrasoundFaceSkinTCTR20220629009Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand30
Active, not recruiting
Phase 1
enalidomide, subcutaneous bortezomib, and dexamethasone treatment for multiple myelomaEUCTR2013-005008-32-IECancer Trials Ireland42
Active, not recruiting
Not Applicable
A phase ii study of the efficacy and safety of lenalidomide combined to escalating doses of chemotherapy in intermediate-2-or high risk MDS and AML with del 5 q31 - GFM-chimio-Rev-08Myelodysplastic Syndrome(MDS) / Acute Myeloid Leukemia(AML)MedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2008-006032-36-FRGroupe Francophone des Myélodysplasies (GFM)